CN113840833B - 基于clec9a的嵌合蛋白复合物 - Google Patents

基于clec9a的嵌合蛋白复合物 Download PDF

Info

Publication number
CN113840833B
CN113840833B CN202080024079.5A CN202080024079A CN113840833B CN 113840833 B CN113840833 B CN 113840833B CN 202080024079 A CN202080024079 A CN 202080024079A CN 113840833 B CN113840833 B CN 113840833B
Authority
CN
China
Prior art keywords
ser
gly
leu
val
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080024079.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN113840833A (zh
Inventor
N·克雷
E·德普拉
L·扎比奥
J·塔威尼尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orinis Bioscience Pte Ltd
Orinis Bioscience Co ltd
Original Assignee
Orinis Bioscience Pte Ltd
Orinis Bioscience Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orinis Bioscience Pte Ltd, Orinis Bioscience Co ltd filed Critical Orinis Bioscience Pte Ltd
Priority to CN202510720099.0A priority Critical patent/CN120590542A/zh
Publication of CN113840833A publication Critical patent/CN113840833A/zh
Application granted granted Critical
Publication of CN113840833B publication Critical patent/CN113840833B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080024079.5A 2019-03-28 2020-03-27 基于clec9a的嵌合蛋白复合物 Active CN113840833B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510720099.0A CN120590542A (zh) 2019-03-28 2020-03-27 基于clec9a的嵌合蛋白复合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962825584P 2019-03-28 2019-03-28
US62/825,584 2019-03-28
US201962906442P 2019-09-26 2019-09-26
US62/906,442 2019-09-26
PCT/US2020/025423 WO2020198662A1 (en) 2019-03-28 2020-03-27 Clec9a-based chimeric protein complexes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510720099.0A Division CN120590542A (zh) 2019-03-28 2020-03-27 基于clec9a的嵌合蛋白复合物

Publications (2)

Publication Number Publication Date
CN113840833A CN113840833A (zh) 2021-12-24
CN113840833B true CN113840833B (zh) 2025-06-17

Family

ID=72609002

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080024079.5A Active CN113840833B (zh) 2019-03-28 2020-03-27 基于clec9a的嵌合蛋白复合物
CN202510720099.0A Pending CN120590542A (zh) 2019-03-28 2020-03-27 基于clec9a的嵌合蛋白复合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510720099.0A Pending CN120590542A (zh) 2019-03-28 2020-03-27 基于clec9a的嵌合蛋白复合物

Country Status (8)

Country Link
US (2) US12351614B2 (https=)
EP (1) EP3947429A4 (https=)
JP (2) JP7773371B2 (https=)
KR (1) KR20220012227A (https=)
CN (2) CN113840833B (https=)
AU (1) AU2020244880A1 (https=)
CA (1) CA3133831A1 (https=)
WO (1) WO2020198662A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7773372B2 (ja) 2019-03-28 2025-11-19 オリオニス バイオサイエンシズ，インコーポレイテッド 線維芽細胞活性化タンパク質結合物質およびその使用
US12351614B2 (en) * 2019-03-28 2025-07-08 Orionis Biosciences, Inc. CLEC9A-based chimeric protein complexes
CN116547003A (zh) * 2020-10-05 2023-08-04 莫纳什大学 Clec9a抗体
EP4724475A2 (en) * 2023-06-09 2026-04-15 Orionis Biosciences, Inc. Clec9a-based chimeric protein formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108883180A (zh) * 2016-02-05 2018-11-23 奥里尼斯生物科学公司 Clec9a结合剂及其用途
CN112512551A (zh) * 2018-03-28 2021-03-16 奥里尼斯生物科学公司股份有限公司 双功能蛋白及其构建

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69007975T2 (de) 1989-08-22 1994-07-21 Immunex Corp Fusionsprotein bestehend aus gm-csf und il-3.
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US20110020273A1 (en) 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
US7947265B2 (en) 2006-08-02 2011-05-24 Mcgill University Fusion proteins and methods for modulation of immune response
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
WO2009003145A1 (en) 2007-06-26 2008-12-31 University Of Miami Antibody-endostatin fusion protein and its variants
GB0805159D0 (en) 2008-03-19 2008-04-23 Sancho Madrid David Immune modulation via C-type lectin
CN101868246A (zh) 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
WO2010030671A1 (en) 2008-09-09 2010-03-18 University Of Medicine And Dentistry Of New Jersey Type i interferon antagonists
US8334101B2 (en) 2008-09-26 2012-12-18 University Of Massachusetts Intracellular DNA receptor
WO2010066740A1 (en) 2008-12-08 2010-06-17 Complix Nv Single-chain antiparallel coiled coil proteins
CA2755983A1 (en) 2009-03-23 2010-09-30 The Walter And Eliza Hall Institute Of Medical Research Compounds and methods for modulating an immune response
JP5764127B2 (ja) 2009-08-17 2015-08-12 ロシュ グリクアート アーゲー 標的化イムノコンジュゲート
JP2013504539A (ja) 2009-09-10 2013-02-07 サイトス バイオテクノロジー アーゲー 糖尿病治療におけるインターロイキン１βムテイン・コンジュゲートの使用
RU2577299C2 (ru) 2011-07-04 2016-03-10 Олег Ильич Эпштейн Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний
US9534056B2 (en) 2011-06-06 2017-01-03 Immungene Inc Engineered TAA antibody-TNFSF member ligand fusion molecules
WO2013053008A2 (en) 2011-10-14 2013-04-18 The Walter And Eliza Hall Institute Of Medical Research Molecules which bind clec9a
EP3559049B1 (en) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
ES2694180T3 (es) 2012-01-20 2018-12-18 Vib Vzw Citocinas de haz alfa-helicoidal mutantes dirigidas
PT2822575T (pt) 2012-03-03 2020-07-02 Immungene Inc Moléculas de fusão anticorpos-mutante de interferão modificadas
EP2872158A1 (en) 2012-05-01 2015-05-20 The University of Sydney Vaccine and uses thereof
CA2878626A1 (en) 2012-08-09 2014-02-13 Roche Glycart Ag Asgpr antibodies and uses thereof
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd８에의 항원 결합 구조체들
EP2992101B1 (en) 2013-04-29 2018-10-10 Agrosavfe N.V. Agrochemical compositions comprising antibodies binding to sphingolipids
KR102322510B1 (ko) 2013-07-18 2021-11-08 브이아이비 브이지더블유 수용체 결합친화성이 현격히 감소된 사이토카인을 수반하는 푸소카인
JP6595988B2 (ja) 2013-07-19 2019-10-23 ヴィブ ブイゼットダブリュー ターゲットされる修飾ｔｎｆファミリーメンバー
BR112016001128A2 (pt) 2013-07-19 2018-01-23 Vib Vzw membros da família il-1 modificados direcionados
SG10202010429YA (en) 2013-07-19 2020-11-27 Vib Vzw Targeting of cytokine antagonists
PT3444271T (pt) 2013-08-08 2022-01-05 Inst Nat Sante Rech Med Modulocinas baseadas em il-15 e no domínio sushi de il-15ralfa
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
WO2016187459A1 (en) 2015-05-20 2016-11-24 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
EP3426278B1 (en) 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
WO2018077893A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
AU2018313810B2 (en) 2017-08-09 2025-05-15 Orionis Biosciences BV Clec9A binding agents and use thereof
EP3664829A4 (en) 2017-08-09 2021-05-05 Orionis Biosciences, Inc. LIAISON OFFICERS AT PD-1 AND PD-L1
CN111511763B (zh) 2017-08-09 2024-05-31 奥里尼斯生物科学有限公司 Cd8结合剂
EP3743448A4 (en) 2018-01-26 2021-11-03 Orionis Biosciences, Inc. XCR1 BINDING AGENTS AND USES THEREOF
KR102877915B1 (ko) 2018-02-05 2025-10-29 오리오니스 바이오사이언시즈 인코포레이티드 섬유아세포 결합제 및 이의 용도
WO2020033646A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
US12351614B2 (en) * 2019-03-28 2025-07-08 Orionis Biosciences, Inc. CLEC9A-based chimeric protein complexes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108883180A (zh) * 2016-02-05 2018-11-23 奥里尼斯生物科学公司 Clec9a结合剂及其用途
CN112512551A (zh) * 2018-03-28 2021-03-16 奥里尼斯生物科学公司股份有限公司 双功能蛋白及其构建

Also Published As

Publication number Publication date
WO2020198662A1 (en) 2020-10-01
US20250353890A1 (en) 2025-11-20
EP3947429A1 (en) 2022-02-09
CN120590542A (zh) 2025-09-05
US12351614B2 (en) 2025-07-08
AU2020244880A1 (en) 2021-10-28
CN113840833A (zh) 2021-12-24
EP3947429A4 (en) 2023-05-17
JP7773371B2 (ja) 2025-11-19
KR20220012227A (ko) 2022-02-03
CA3133831A1 (en) 2020-10-01
JP2022530742A (ja) 2022-07-01
JP2025118769A (ja) 2025-08-13
US20220153801A1 (en) 2022-05-19
WO2020198662A8 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
JP7820448B2 (ja) 新規のサイトカインプロドラッグ
US11845806B2 (en) Proteinaceous heterodimer and use thereof
CN113840833B (zh) 基于clec9a的嵌合蛋白复合物
CN109641046B (zh) 单链可变片段cd3结合蛋白质
CN107849148B (zh) 三特异性结合蛋白质及使用方法
ES2469676T3 (es) Complejos moleculares dim�ricos
ES2711377T3 (es) Molécula Fv de unión a antígenos multivalente
CN103068847A (zh) 可活化的双特异性抗体
WO2020252907A1 (zh) 抗cd3e和bcma双特异性抗体及其用途
CN112409483A (zh) 抗pd-l1纳米抗体
WO2022022709A1 (zh) 一种SIRPα-Fc融合蛋白
JP7837331B2 (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
CN115052897B (zh) PLAP-CD3ε双特异性抗体
JP2017095417A (ja) 抗癌剤
WO2023222035A1 (zh) 抗tigit抗体与il2的融合蛋白或其变体及其应用
CN116554343B (zh) 一种长效重组人生长激素及其应用
RU2800164C2 (ru) Биспецифическое антитело против cd3e/bcma и его применение
KR20250171367A (ko) Steap2 지향성 t 세포 결합제 및 이의 조성물
WO2024174743A1 (zh) 一种靶向αvβ3和CD47的双功能融合蛋白以及其应用
JP5600758B2 (ja) 二量体分子複合体
JP2026513991A (ja) Ｓｔｅａｐ２指向性ｔ細胞エンゲージャー及びその組成物
CN120530135A (zh) 抗b7h3抗体和使用方法
NZ794344A (en) Tgfβr2 extracellular domain truncated molecule, fusion protein of tgfβr2 extracellular domain truncated molecule and anti-egfr antibody, and anti-tumor use of fusion protein
NZ794344B2 (en) TGFßR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE, FUSION PROTEIN OF TGFßR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE AND ANTI-EGFR ANTIBODY, AND ANTI-TUMOR USE OF FUSION PROTEIN
HK1184472B (zh) 可活化的双特异性抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant